GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. / Foo, Cheng Xiang; Bartlett, Stacey; Chew, Keng Yih; Ngo, Minh Dao; Bielefeldt-Ohmann, Helle; Arachchige, Buddhika Jayakody; Matthews, Benjamin; Reed, Sarah; Wang, Ran; Smith, Christian; Sweet, Matthew J.; Burr, Lucy; Bisht, Kavita; Shatunova, Svetlana; Sinclair, Jane E.; Parry, Rhys; Yang, Yuanhao; Lévesque, Jean Pierre; Khromykh, Alexander; Rosenkilde, Mette Marie; Short, Kirsty R.; Ronacher, Katharina.
In: The European respiratory journal, Vol. 61, No. 3, 2201306, 2023.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection
AU - Foo, Cheng Xiang
AU - Bartlett, Stacey
AU - Chew, Keng Yih
AU - Ngo, Minh Dao
AU - Bielefeldt-Ohmann, Helle
AU - Arachchige, Buddhika Jayakody
AU - Matthews, Benjamin
AU - Reed, Sarah
AU - Wang, Ran
AU - Smith, Christian
AU - Sweet, Matthew J.
AU - Burr, Lucy
AU - Bisht, Kavita
AU - Shatunova, Svetlana
AU - Sinclair, Jane E.
AU - Parry, Rhys
AU - Yang, Yuanhao
AU - Lévesque, Jean Pierre
AU - Khromykh, Alexander
AU - Rosenkilde, Mette Marie
AU - Short, Kirsty R.
AU - Ronacher, Katharina
N1 - Publisher Copyright: Copyright ©The authors 2023.
PY - 2023
Y1 - 2023
N2 - RATIONALE: Severe viral respiratory infections are often characterised by extensive myeloid cell infiltration and activation and persistent lung tissue injury. However, the immunological mechanisms driving excessive inflammation in the lung remain poorly understood. OBJECTIVES: To identify the mechanisms that drive immune cell recruitment in the lung during viral respiratory infections and identify novel drug targets to reduce inflammation and disease severity. METHODS: Preclinical murine models of influenza A virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. RESULTS: Oxidised cholesterols and the oxysterol-sensing receptor GPR183 were identified as drivers of monocyte/macrophage infiltration to the lung during influenza A virus (IAV) and SARS-CoV-2 infection. Both IAV and SARS-CoV-2 infection upregulated the enzymes cholesterol 25-hydroxylase (CH25H) and cytochrome P450 family 7 subfamily member B1 (CYP7B1) in the lung, resulting in local production of the oxidised cholesterols 25-hydroxycholesterol (25-OHC) and 7α,25-dihydroxycholesterol (7α,25-OHC). Loss-of-function mutation of Gpr183 or treatment with a GPR183 antagonist reduced macrophage infiltration and inflammatory cytokine production in the lungs of IAV- or SARS-CoV-2-infected mice. The GPR183 antagonist significantly attenuated the severity of SARS-CoV-2 infection and viral loads. Analysis of single-cell RNA-sequencing data on bronchoalveolar lavage samples from healthy controls and COVID-19 patients with moderate and severe disease revealed that CH25H, CYP7B1 and GPR183 are significantly upregulated in macrophages during COVID-19. CONCLUSION: This study demonstrates that oxysterols drive inflammation in the lung via GPR183 and provides the first preclinical evidence for the therapeutic benefit of targeting GPR183 during severe viral respiratory infections.
AB - RATIONALE: Severe viral respiratory infections are often characterised by extensive myeloid cell infiltration and activation and persistent lung tissue injury. However, the immunological mechanisms driving excessive inflammation in the lung remain poorly understood. OBJECTIVES: To identify the mechanisms that drive immune cell recruitment in the lung during viral respiratory infections and identify novel drug targets to reduce inflammation and disease severity. METHODS: Preclinical murine models of influenza A virus and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. RESULTS: Oxidised cholesterols and the oxysterol-sensing receptor GPR183 were identified as drivers of monocyte/macrophage infiltration to the lung during influenza A virus (IAV) and SARS-CoV-2 infection. Both IAV and SARS-CoV-2 infection upregulated the enzymes cholesterol 25-hydroxylase (CH25H) and cytochrome P450 family 7 subfamily member B1 (CYP7B1) in the lung, resulting in local production of the oxidised cholesterols 25-hydroxycholesterol (25-OHC) and 7α,25-dihydroxycholesterol (7α,25-OHC). Loss-of-function mutation of Gpr183 or treatment with a GPR183 antagonist reduced macrophage infiltration and inflammatory cytokine production in the lungs of IAV- or SARS-CoV-2-infected mice. The GPR183 antagonist significantly attenuated the severity of SARS-CoV-2 infection and viral loads. Analysis of single-cell RNA-sequencing data on bronchoalveolar lavage samples from healthy controls and COVID-19 patients with moderate and severe disease revealed that CH25H, CYP7B1 and GPR183 are significantly upregulated in macrophages during COVID-19. CONCLUSION: This study demonstrates that oxysterols drive inflammation in the lung via GPR183 and provides the first preclinical evidence for the therapeutic benefit of targeting GPR183 during severe viral respiratory infections.
UR - http://www.scopus.com/inward/record.url?scp=85150001288&partnerID=8YFLogxK
U2 - 10.1183/13993003.01306-2022
DO - 10.1183/13993003.01306-2022
M3 - Journal article
C2 - 36396144
AN - SCOPUS:85150001288
VL - 61
JO - The European respiratory journal
JF - The European respiratory journal
SN - 0903-1936
IS - 3
M1 - 2201306
ER -
ID: 340403715